Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

676
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
676
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.5K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

610
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
610
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

579
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
579

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tapinarof cream 1% for corticosteroid-refractory erythema annulare centrifugum: A first reported case.

JAAD case reports·2026
Same author

Modestly Increased Incidence of Irritable Bowel Syndrome in Hidradenitis Suppurativa: A Retrospective Cohort Study Using TriNetX.

International journal of dermatology·2026
Same author

Response to Choi et al, "Pathergy beyond neutrophilic dermatoses: A case of localized leukemia cutis at the site of intravenous infiltration".

JAAD case reports·2026
Same author

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.

JAMA dermatology·2025
Same author

Refractory cutaneous pseudolymphoma treated with tapinarof.

Proceedings (Baylor University. Medical Center)·2025
Same author

A linear purpuric rash in an elderly man.

JAAD case reports·2025
Same journal

Systemic therapy for advanced cutaneous squamous cell carcinoma.

Seminars in cutaneous medicine and surgery·2019
Same journal

Atypical Fibroxanthoma.

Seminars in cutaneous medicine and surgery·2019
Same journal

Introduction, High-Risk Skin Cancer.

Seminars in cutaneous medicine and surgery·2019
Same journal

Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care.

Seminars in cutaneous medicine and surgery·2019
Same journal

MoleMapper: an application for crowdsourcing mole images to advance melanoma early-detection research.

Seminars in cutaneous medicine and surgery·2019
Same journal

Digital imaging applications and informatics in dermatology.

Seminars in cutaneous medicine and surgery·2019
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

940

IL-17 inhibitors for psoriasis.

So Yeon Paek1,2, Jillian Frieder3, Dario Kivelevitch3

  • 1Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA. doctor.paek@gmail.com.

Seminars in Cutaneous Medicine and Surgery
|September 15, 2018
PubMed
Summary
This summary is machine-generated.

The Th17/interleukin-23 pathway is key in psoriasis. Approved treatments targeting interleukin-17A or its receptor offer clinical efficacy for moderate-to-severe plaque psoriasis.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Detection and Isolation of Viable Mouse IL-17-Secreting T Cells
12:38

Detection and Isolation of Viable Mouse IL-17-Secreting T Cells

Published on: December 18, 2008

11.6K

Related Experiment Videos

Last Updated: Feb 5, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

940
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Detection and Isolation of Viable Mouse IL-17-Secreting T Cells
12:38

Detection and Isolation of Viable Mouse IL-17-Secreting T Cells

Published on: December 18, 2008

11.6K

Area of Science:

  • Immunodermatology
  • Molecular biology
  • Pharmacology

Background:

  • The Th17/interleukin (IL)-23 pathway is integral to the pathogenesis of psoriasis.
  • The IL-17 cytokine family comprises six members: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F.

Purpose of the Study:

  • To review the clinical efficacy, safety, and tolerability of biologic agents targeting the IL-17 pathway for psoriasis treatment.

Main Methods:

  • Literature review of clinical trials and studies on IL-17-targeted therapies.
  • Analysis of data on secukinumab, ixekizumab, and brodalumab.

Main Results:

  • Secukinumab and ixekizumab target IL-17A, while brodalumab targets the IL-17 receptor.
  • These agents have demonstrated clinical efficacy in moderate-to-severe plaque psoriasis.

Conclusions:

  • Targeting the IL-17 pathway provides effective treatment options for moderate-to-severe plaque psoriasis.
  • Understanding the efficacy, safety, and tolerability profiles of these agents is crucial for clinical practice.